克拉屈滨联合低剂量全身照射用于急性髓系白血病造血干细胞移植的I/II期多中心试验
这项前瞻性I/II期多中心试验评估克拉屈滨联合2 Gy全身照射作为不适合强化预处理方案的成人急性髓系白血病患者异基因造血干细胞移植的非清髓性预处理。6个月复发率为16%,达到预设主要疗效终点,2年总生存55%,无白血病生存52%,对比历史高危队列显示更低的总死亡率、疾病进展或死亡及形态学复发风险。
要点
- 克拉屈滨联合2 Gy TBI非清髓预处理在成人AML中6个月复发率16%,达到主要终点。
- 2年总生存55%,无白血病生存52%,所有患者均成功植入。
- 对比历史氟达拉滨-TBI队列,克拉屈滨-TBI方案总死亡率和复发风险更低,非复发死亡率相当。
核心结论
- 克拉屈滨联合2 Gy TBI作为非清髓性预处理在不符合强化方案条件的成人AML中可行,6个月复发率16%达到预设主要疗效终点。
- 与历史氟达拉滨-TBI高危队列相比,克拉屈滨-TBI方案总死亡率、疾病进展或死亡及形态学复发风险更低,非复发死亡率相当。
研究设计与样本
- 克拉屈滨剂量150-250 mg/m2联合2 Gy TBI作为非清髓性预处理,其中36例接受最大方案指定剂量。
主要发现
- 所有患者均完全植入;1例发生多因素急性肾损伤,1例发生多器官衰竭,未观察到其他3-5级非血液学毒性。
- 全部患者6个月复发率为16%(95% CI,5%-27%),接受最大剂量高危患者为14%(95% CI,3%-26%)。
- 2年总生存55%(95% CI,40%-70%),无白血病生存52%(95% CI,37%-67%)。
- 对比历史高危队列(氟达拉滨90 mg/m2联合2 Gy TBI),总死亡率HR 0.50(95% CI,0.28-0.91),疾病进展或死亡HR 0.48(95% CI,0.27-0.85),形态学复发HR 0.30(95% CI,0.13-0.69),非复发死亡HR 0.85(95% CI,0.36-2.00)。
关键数值与推荐
- 主要疗效终点为6个月复发率,预设目标未明确报告,但结果达到预设主要疗效终点。
- 克拉屈滨剂量范围为150-250 mg/m2,最大方案指定剂量为250 mg/m2(36例接受)。
临床怎么用
- 对于不适合强化预处理的成人AML患者,克拉屈滨联合2 Gy TBI可作为非清髓性预处理选择,需进一步研究验证。
- 该方案在高危AML患者中显示出较低的复发和死亡风险,但需关注肾损伤和多器官衰竭等毒性。
局限性
- 随访时间有限,长期疗效和安全性需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clofarabine is an immunosuppressive purine nucleoside analog that may have better anti-leukemic activity than fludarabine. We performed a prospective phase I/II multisite trial of clofarabine with 2 Gy total body irradiation as non-myeloablative conditioning for allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia who were unfit for more intense regimens. Our main objective was to improve the 6-month relapse rate following non-myeloablative conditioning, while maintaining historic rates of non-relapse mortality (NRM) and engraftment. Forty-four patients, 53 to 74 (median: 69) years, were treated with clofarabine at 150 to 250 mg/m2 , of whom 36 were treated at the maximum protocol-specified dose. One patient developed multifactorial acute kidney injury and another developed multiorgan failure, but no other grade 3 to 5 non-hematologic toxicities were observed. All patients fully engrafted. The 6-month relapse rate was 16% (95% CI, 5%-27%) among all patients and 14% (95% CI, 3%-26%) among high-risk patients treated at the maximum dose, meeting the pre-specified primary efficacy endpoint. Overall survival was 55% (95% CI, 40%-70%) and leukemia-free survival was 52% (95% CI, 37%-67%) at 2 years. Compared to a historical high-risk cohort treated with the combination of fludarabine at 90 mg/m2 and 2 Gy TBI, protocol patients treated with the clofarabine-TBI regimen had lower rates of overall mortality (HR of 0.50, 95% CI, 0.28-0.91), disease progression or death (HR 0.48, 95% CI, 0.27-0.85), and morphologic relapse (HR 0.30, 95% CI, 0.13-0.69), and comparable NRM (HR 0.85, 95% CI 0.36-2.00). The combination of clofarabine with TBI warrants further investigation in patients with high-risk AML.
引用
- Krakow EF, Gyurkocza B, Storer BE, et al. Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. Am J Hematol. 2019. PMID: 31637757. doi:10.1002/ajh.25665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。